文献速递介入腹部外周血管DSA

动脉栓塞治疗消化性溃疡出血的十年经验:N-丁基氰基丙烯酸酯胶与其他栓塞剂的比较

Ten-year experience with arterial embolization for peptic ulcer bleeding: N-butyl cyanoacrylate glue versus other embolic agents.
PubMed 文献 · Eur Radiol · 2020-10-31

这项回顾性研究纳入148例难治性消化性溃疡出血患者,比较以Glubran®2 N-丁基氰基丙烯酸酯胶(NBCA-MS)为主与其他栓塞剂行经导管动脉栓塞的疗效。结果显示NBCA-MS组早期再出血显著少于其他栓塞剂组,30天死亡率两组相似,NBCA-MS组透视时间显著更短,总体并发症率相似。

要点

  • NBCA-MS组早期再出血显著少于其他栓塞剂组(OR 0.47,95%CI 0.22-0.99,p=0.047)。
  • 单独使用弹簧圈与早期再出血显著增多相关(OR 20.4,95%CI 10.13-50.14,p=0.024)。
  • NBCA-MS组透视时间显著短于其他栓塞剂组(20.8±11.5 min vs 35.5±23.4 min,p=0.002)。

诊断标准与关键数值

  • 技术成功率为95.3%,主要临床成功率为64.5%。
  • 早期再出血率为35.4%,30天死亡率为21.3%。
  • NBCA-MS组早期再出血显著少于其他栓塞剂组(OR 0.47,95%CI 0.22-0.99,p=0.047)。
  • 单独使用弹簧圈与早期再出血显著增多相关(OR 20.4,95%CI 10.13-50.14,p=0.024)。
  • 两种或以上合并症是早期再出血的唯一其他独立相关因素(OR 20.14,95%CI 10.01-40.52,p=0.047)。

临床应用与阅片要点

  • 作者认为NBCA-MS相比其他栓塞剂具有多项优势,用于动脉栓塞治疗难治性消化性溃疡出血时可提供快速止血,应作为一线治疗。
  • NBCA-MS组与其他栓塞剂组的30天死亡率相似。
  • 较低的初始血红蛋白水平与较高的30天死亡率显著相关(OR 10.38,95%CI 10.10-10.74,p=0.006)。
  • NBCA-MS组与其他栓塞剂组的总体并发症率相似(分别为10.7% vs 9.1%,p=0.786)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: To compare our experience with N-butyl cyanoacrylate glue as the primary embolic agent versus other embolic agents for transcatheter arterial embolization (TAE) in refractory peptic ulcer bleeding and to identify factors associated with early rebleeding and 30-day mortality.

METHODS: Retrospective study of 148 consecutive patients comparing the clinical success rate in 78 patients managed with Glubran®2 N-butyl cyanoacrylate metacryloxysulfolane (NBCA-MS) alone or with other agents and 70 with other embolic agents only (coils, microspheres, ethylene-vinyl alcohol copolymer, or gelatin sponge) at a university center in 2008-2019. Univariate and multivariate logistic regression analyses were done to identify prognostic factors.

RESULTS: The technical success rate was 95.3% and the primary clinical success was 64.5%. The early rebleeding and day-30 mortality rates were 35.4% and 21.3%, respectively. Rebleeding was significantly less common with than without Glubran®2 (OR, 0.47; 95% CI, 0.22-0.99; p = .047) and significantly more common with coils used alone (OR, 20.4; 95% CI, 10.13-50.14; p = .024). The only other factor independently associated with early rebleeding was having two or more comorbidities (OR, 20.14; 95% CI, 10.01-40.52; p = .047). Day-30 mortality was similar in the two treatment groups. A lower initial hemoglobin level was significantly associated with higher day-30 mortality (OR, 10.38; 95% CI, 10.10-10.74; p = .006). Fluoroscopy time was significantly shorter with Glubran®2 (20.8 ± 11.5 min vs. 35.5 ± 23.4 min, p = .002). Both groups (Glubran®2 vs. other agents) had similar rates of overall complications (10.7% vs. 9.1%, respectively, p = .786).

CONCLUSIONS: Glubran®2 NBCA-MS as the primary agent allowed for faster and better clinical success compared to other embolic agents when used for TAE to safely stop refractory peptic ulcer bleeding.

KEY POINTS: • Choice of embolic agent for arterial embolization of refractory peptic ulcer bleeding is still debated. We compared our experience with N-butyl cyanoacrylate (NBCA) glue vs. other embolic agents. • The use of Glubran®2 NBCA glue in the endovascular management of refractory peptic ulcer bleeding was significantly faster and more effective, and at least as safe compared to other embolic agents. • NBCA glue offers several advantages compared to other embolic agents and provides rapid hemostasis when used for arterial embolization to treat refractory peptic ulcer bleeding. It should be the first-line therapy.

来源:Eur Radiol,查看原文。版权归原作者所有。

引用

  1. Loffroy R, Desmyttere AS, Mouillot T, et al. Ten-year experience with arterial embolization for peptic ulcer bleeding: N-butyl cyanoacrylate glue versus other embolic agents. Eur Radiol. 2020. PMID: 33128601. doi:10.1007/s00330-020-07427-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。